Cure­Vac seeks to ac­cel­er­ate vac­cine in­fringe­ment case against Pfiz­er and BioN­Tech

Cure­Vac is go­ing on the of­fen­sive against Pfiz­er and BioN­Tech, say­ing that it will seek to ac­cel­er­ate its lit­i­ga­tion around patents re­lat­ed to the man­u­fac­ture of the Covid-19 vac­cine Comir­naty.

The Ger­man biotech com­pa­ny an­nounced Fri­day that the case, which orig­i­nal­ly launched in the US last sum­mer, has been trans­ferred from the fed­er­al dis­trict court of Mass­a­chu­setts to the east­ern dis­trict court in Vir­ginia as part of an ef­fort to speed up the lit­i­ga­tion, po­ten­tial­ly al­low­ing for a tri­al as soon as next year.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN